Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JD Health International, Inc. ( (HK:6618) ) has issued an update.
JD Health International reported strong unaudited results for the first quarter of 2026, with revenue rising 17.0% year on year to RMB19.47 billion and operating income surging 70.4%. Profit for the period jumped 78.2% to RMB1.66 billion, while non-IFRS profit grew a more modest 6.0%, underscoring both robust operational leverage and the impact of adjustments such as share-based payments.
Operationally, the company deepened its role as a key online marketplace for innovative drug launches, introducing more than 30 new medicines including Novartis’ Phapsido and Lumirix for vitiligo. It also expanded strategic partnerships with multinational and domestic pharmaceutical firms and integrated its AI medical assistant “AI Jingyi” across the full care loop, driving a surge in usage of its AI agent and strengthening its digital health ecosystem.
In a move that may mitigate shareholder dilution, JD Health plans to establish a trust to buy back shares on the market for use in its share incentive schemes. By using repurchased shares instead of issuing new equity to satisfy awards and options, the company aims to better align employee incentives with investor interests while managing its capital structure more efficiently.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$71.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International Inc. is a Hong Kong–listed online healthcare platform operating in the digital medical and pharmaceutical services industry. The group offers online consultations, AI-powered medical assistance, diagnostics, and pharmaceutical retail through JD Pharmacy, with a focus on new drug launches and integrated online-to-offline healthcare services in China.
Average Trading Volume: 7,752,265
Technical Sentiment Signal: Sell
Current Market Cap: HK$146.2B
Learn more about 6618 stock on TipRanks’ Stock Analysis page.